Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OPKO Health’s filings can feel like two companies in one: a nationwide genetics lab and a global pharmaceutical innovator. Digging through a 300-page disclosure to spot how BioReference’s testing volumes offset R&D spend—or to see when executives buy shares before an FDA catalyst—takes time. That is why investors search for “OPKO Health SEC filings explained simply” and often end up buried in footnotes.
Stock Titan solves this pain. Our AI parses every OPKO Health annual report 10-K simplified, flags segment revenue in the OPKO Health quarterly earnings report 10-Q filing, and delivers instant context for each OPKO Health 8-K material events explained. Need real-time alerts? We stream OPKO Health Form 4 insider transactions real-time so you never miss a trade. Whether you’re understanding OPKO Health SEC documents with AI for pipeline milestones or comparing cash burn trends, our platform turns dense pages into clear insights.
Here’s what you’ll find on this page:
- OPKO Health insider trading Form 4 transactions & OPKO Health executive stock transactions Form 4
- OPKO Health earnings report filing analysis drawn from 10-Qs and management commentary
- OPKO Health proxy statement executive compensation details, from equity grants to bonus metrics
- AI-powered summaries, red-flag highlights, and filing-to-filing comparisons
- Real-time EDGAR updates across all forms—10-K, 10-Q, 8-K, S-3, SC 13G, and more
Stop scrolling through PDFs line by line. Stock Titan’s expert analysis translates OPKO Health’s complex lab operations, global manufacturing notes, and drug-development disclosures into the actionable data investors actually use.
Viasat Inc. (VSAT) – Form 4 insider filing
On 07 July 2025, Girish Chandran, President, Global Space Networks, reported the vesting of 8,334 restricted stock units (transaction code “M”). The RSUs converted 1-for-1 into common shares at no cost. To satisfy payroll-tax obligations, 4,488 shares were automatically surrendered to the company at $15.93 per share (code “F”), leaving a net increase of 3,846 shares in Chandran’s direct holdings.
Post-transaction ownership: 46,255 direct shares, 5,644 shares in the officer’s 401(k) and 176 in a spouse 401(k), plus 16,666 unvested RSUs remaining from the original 25,000-unit grant dated 06 Jun 2024. The next two RSU tranches are scheduled to vest on the second and third anniversaries of that grant, subject to continued employment.
No open-market purchase or sale occurred; the filing reflects routine equity-compensation vesting and tax withholding. Therefore, the signal for investors is considered neutral with limited immediate impact on Viasat’s valuation.
FAQ
What is the current stock price of Opko Health (OPK)?
What is the market cap of Opko Health (OPK)?
What are the primary business segments of OPKO Health?
How does OPKO Health generate revenue?
What distinguishes OPKO Health's diagnostics operations?
How is OPKO Health positioned within the pharmaceutical sector?
What role do global operations play in OPKO Health's business model?
How does OPKO Health maintain its competitive edge in the healthcare industry?
How has OPKO Health strategically streamlined its operations?
What are the key markets served by OPKO Health?
